BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) shares were up 1.4% during trading on Friday . The stock traded as high as $2.97 and last traded at $2.91, with a volume of 179,485 shares. The stock had previously closed at $2.87.

A number of brokerages have recently issued reports on BCRX. FBR & Co reiterated a “buy” rating and set a $6.00 price target on shares of BioCryst Pharmaceuticals in a research report on Wednesday, July 6th. Jefferies Group upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Wednesday, June 1st. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, May 9th. Finally, Zacks Investment Research downgraded BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 9th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $9.70.

The company has a 50-day moving average price of $3.09 and a 200 day moving average price of $3.84. The company’s market cap is $218.13 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.08. The business earned $4.82 million during the quarter, compared to analyst estimates of $5.42 million. The firm’s quarterly revenue was down 29.4% on a year-over-year basis. During the same period last year, the firm posted ($0.21) EPS. Equities analysts predict that BioCryst Pharmaceuticals Inc. will post ($1.06) earnings per share for the current fiscal year.

Other hedge funds recently modified their holdings of the company. Morgan Stanley boosted its stake in shares of BioCryst Pharmaceuticals by 13.9% in the fourth quarter. Morgan Stanley now owns 103,804 shares of the biotechnology company’s stock worth $1,071,000 after buying an additional 12,646 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of BioCryst Pharmaceuticals by 1.8% in the fourth quarter. Jennison Associates LLC now owns 1,348,563 shares of the biotechnology company’s stock worth $13,917,000 after buying an additional 24,014 shares during the last quarter. Finally, Globeflex Capital L P bought a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth approximately $1,241,000.

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.